OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
Episode Details
The recent episode of the All-In Podcast featured a wide-ranging discussion led by hosts Jason Calacanis, David Friedberg, David Sacks, and Chamath Palihapitiya. They started by analyzing how OpenAI, under Sam Altman, alongside Sarah Frier and Greg Brockman, reportedly missed targets for ChatGPT. However, the company is advancing rapidly with GPT 5.5 and the Codex model, keeping them competitive against anthropic and its CEO Dario Amodei, who are managing compute constraints with Claude and Opus 4.7. Elon Musk continues to challenge the landscape with Grok and leveraging computing excess from SpaceX, all while pursuing Elon Musk's lawsuit against OpenAI. The hosts highlighted how Hyperscalers like Google (pushing Gemini), Microsoft, Amazon, Meta, and Oracle are driving a historic Capex Boom centered around Cloud Computing. This massive AI Infrastructure Buildout is creating unprecedented Energy demand for AI, prompting interest in highly efficient SLMs (Small Language Models). In the developer space, Aaron Levie criticized the hype around Vibe Coding, noting risks highlighted when a non-engineer using Cursor 2.0 accidentally deleted a codebase. In the enterprise software sector, Cybersecurity in the AI era is exploding. Executives like George Kurtz of CrowdStrike and leaders at Palo Alto Networks see immense opportunities to defend against both domestic threats and foreign models like China's Deep Seek, as well as sophisticated models like Anthropic's Mythos. Shifting to biotechnology, the conversation covered the explosive popularity of GLP-1 Agonists. Eli Lilly is seeing massive success with Tirzepatide and is now testing the next-generation peptide Retatrutide. Finally, the episode concluded with a look at the Supreme Court, where the hosts discussed oral arguments involving Bayer and the EPA. This high-stakes case is deeply influenced by the recent overturning of the Chevron Doctrine and ongoing debates over Federal Preemption.
Key Topics & People
.jpg?width=300){kind=avatar}
Podcast host highlighting market indicators and tech valuations.
.jpg?width=300){kind=avatar}
.jpg?width=300){kind=avatar}
Massive cloud providers like AWS, GCP, and Azure that control the majority of AI compute.
CEO of Anthropic, noted for his doomerism messaging regarding AI risks.
.jpg?width=300){kind=avatar}
An angel investor steering discourse around tech platform decay, advising founders against taking venture debt that restricts future agility.
A life sciences investor and entrepreneur actively exploring how big data and epigenetics can solve systemic biological threats.
A highly influential venture capitalist bridging the gap between Silicon Valley's tech ambitions and Washington DC policy frameworks.
Podcast hosting the interview with Steve Hilton.
_(cropped).jpg?width=300){kind=avatar}
President and co-founder of OpenAI, known for his foresight on compute needs.
.jpg?width=300){kind=avatar}
CEO of OpenAI, heavily involved in securing massive compute and energy infrastructure.
An OpenAI model focused on coding assistance that rapidly scaled to 5 million users.
CFO of OpenAI who discusses the company's recent fundraising, infrastructure strategies, and market positioning.
The practice of building software and applications using AI language models rather than writing code manually.
The massive capital expenditure cycle dedicated to constructing data centers, deploying GPUs, and powering AI development.
A new triple-agonist peptide drug by Eli Lilly showing spectacular fat loss and liver health improvements.
The delivery of computing services over the internet, experiencing a massive boom due to AI workloads.
The principle that federal laws supersede state laws, heavily debated in current corporate product liability cases.
A recently overturned legal precedent regarding federal agency deference that impacts corporate regulations.
The highest federal court in the US, currently ruling on complex corporate regulation cases.
A class of peptide medications that manage blood sugar and drive significant weight loss.
A dual-agonist GLP-1 and GIP drug marketed by Eli Lilly for metabolic health.
CEO of CrowdStrike, discussing the immense enterprise demand for AI-driven security tools.
A major security firm noted for leading the charge in AI-powered cybersecurity defense.
A cybersecurity leader actively integrating AI models to defend against emerging digital threats.
The transformation of security defense and offense using highly capable autonomous AI models.
Tech CEO who criticized the unrealistic expectations of unmanaged vibe coding by non-engineers.
An AI-assisted code editor used heavily for agentic software development and vibe coding.
More efficient, localized AI models designed to reduce energy inference costs.
The massive electrical power required to operate advanced AI compute facilities.
The massive surge in capital expenditures by tech companies to build AI capabilities.
A high-stakes trial where Elon Musk accuses OpenAI of unjust enrichment and abandoning its nonprofit mission.